I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Monopar Therapeutics (MNPR), raising the price target from $105 to $125. The upgrade reflects significant progress in the rolling NDA for ALXN1840 for Wilson disease, supported by FDA designations and robust Phase 3 clinical data demonstrating superior copper mobilization. These factors reduce execution risk and enhance the regulatory path visibility.
In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Monopar Therapeutics Inc, with a price target of $125.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Andres Y. Maldonado has given his Buy rating due to a combination of factors, chiefly the meaningful progress in Monopar’s regulatory strategy for ALXN1840 in Wilson disease. The initiation of a rolling NDA, backed by Fast Track, Orphan Drug, and Rare Pediatric Disease designations, signals both FDA engagement and the potential future value of a Priority Review Voucher if approval is achieved.
He also points to a strong and coherent clinical dataset that underpins the filing, including Phase 3 results showing superior copper mobilization and broad clinical benefits versus standard therapies, alongside long-term safety data across hundreds of patient-years. With these developments reducing execution risk and enhancing the visibility of the regulatory path, Maldonado reiterates his Buy rating and revises his price target upward from $105 to $125, reflecting an improved risk-reward profile for MNPR.
Y. Maldonado covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Verastem, and ImmunityBio. According to TipRanks, Y. Maldonado has an average return of 44.4% and a 56.15% success rate on recommended stocks.